These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1140 related items for PubMed ID: 19672093

  • 1. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
    Gadermaier E, Flicker S, Aberer W, Egger C, Reider N, Focke M, Vrtala S, Kundi M, Valenta R.
    Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
    [Abstract] [Full Text] [Related]

  • 2. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R.
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [Abstract] [Full Text] [Related]

  • 3. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B, Schiller D, Möbs C, de Jong NW, Ebner C, Reider N, Bartel D, Lidholm J, Pfützner W, Gerth van Wijk R, Vieths S, Bohle B.
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [Abstract] [Full Text] [Related]

  • 4. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E.
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.
    Int Arch Allergy Immunol; 2008 Oct; 145(3):193-206. PubMed ID: 17912007
    [Abstract] [Full Text] [Related]

  • 6. Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens.
    Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R.
    J Allergy Clin Immunol; 2000 Apr; 105(4):803-13. PubMed ID: 10756233
    [Abstract] [Full Text] [Related]

  • 7. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study.
    Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F.
    Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):119-22. PubMed ID: 17523385
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens.
    Bohle B, Radakovics A, Lüttkopf D, Jahn-Schmid B, Vieths S, Ebner C.
    Clin Exp Allergy; 2005 Oct; 35(10):1392-9. PubMed ID: 16238801
    [Abstract] [Full Text] [Related]

  • 9. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Würtzen PA, Hertl M, Pfützner W.
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [Abstract] [Full Text] [Related]

  • 10. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
    Cudowska B, Kaczmarski M, Restani P.
    Rocz Akad Med Bialymst; 2005 Nov; 50():268-73. PubMed ID: 16358981
    [Abstract] [Full Text] [Related]

  • 11. Birch-apple syndrome treated with birch pollen immunotherapy.
    Mauro M, Russello M, Incorvaia C, Gazzola G, Frati F, Moingeon P, Passalacqua G.
    Int Arch Allergy Immunol; 2011 Nov; 156(4):416-22. PubMed ID: 21832831
    [Abstract] [Full Text] [Related]

  • 12. [IgE and IgG antibody response in patients with type I allergy to birch pollen].
    Rumpold H, Jarolim E, Bonitz W, Tejkl M, Breitenbach M, Scheiner O, Kraft D.
    Wien Klin Wochenschr; 1989 Feb 03; 101(3):107-10. PubMed ID: 2922932
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE, Monasterolo G.
    Int Arch Allergy Immunol; 2004 Sep 03; 135(1):44-53. PubMed ID: 15286445
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M, Kinaciyan T, Nagl B, Baumgartner-Durchschlag U, Huber H, Ebner C, Lidholm J, Bartel D, Vieths S, Jahn-Schmid B, Bohle B.
    J Allergy Clin Immunol; 2013 Jan 03; 131(1):94-102. PubMed ID: 22921871
    [Abstract] [Full Text] [Related]

  • 16. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M.
    Int Arch Allergy Immunol; 2005 Sep 03; 138(1):59-66. PubMed ID: 16103688
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens.
    Jahn-Schmid B, Radakovics A, Lüttkopf D, Scheurer S, Vieths S, Ebner C, Bohle B.
    J Allergy Clin Immunol; 2005 Jul 03; 116(1):213-9. PubMed ID: 15990797
    [Abstract] [Full Text] [Related]

  • 19. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
    Rask C, Lund L, Lund G, Heydenreich B, Wurtzen P, Bellinghausen I, Saloga J, Lund K.
    Clin Exp Allergy; 2012 Sep 03; 42(9):1356-68. PubMed ID: 22925322
    [Abstract] [Full Text] [Related]

  • 20. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C, Slotosch C, Löffler H, Jakob T, Hertl M, Pfützner W.
    J Immunol; 2010 Feb 15; 184(4):2194-203. PubMed ID: 20048125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.